502 results
P
I/C
l, o, w, -, l, e, v, e, l, , a, r, s, e, n, i, c, , (, A, s, ), , c, o, n, c, e, n, t, r, a, t, i, o, n, , i, n, , d, r, i, n, k, i, n, g, , w, a, t, e, r, d, r, i, n, k, i, n, g, , w, a, t, e, r, , A, s, , c, o, n, c, e, n, t, r, a, t, i, o, n, s, , l, o, w, e, r, , t, h, a, n, , t, h, e, , W, H, O, , p, r, o, v, i, s, i, o, n, a, l, , g, u, i, d, e, l, i, n, e, , v, a, l, u, e, , (, 1, 0, , µ, g, /, L, )
O
p, o, o, l, e, d, , a, s, s, o, c, i, a, t, i, o, n, , b, e, t, w, e, e, n, , t, h, e, , r, e, l, a, t, i, v, e, , r, i, s, k, , o, f, , e, a, c, h, , c, a, r, d, i, o, v, a, s, c, u, l, a, r, , d, i, s, e, a, s, e, , (, C, V, D, ), , e, n, d, p, o, i, n, t, , a, n, d, , l, o, w, -, l, e, v, e, l, , A, s, , c, o, n, c, e, n, t, r, a, t, i, o, n, , i, n, , d, r, i, n, k, i, n, g, , w, a, t, e, r
P
Hepatocellular carcinomas (HCCs), non-HCC malignancies
I/C
Contrast-enhanced ultrasound (CEUS) Liver Imaging Reporting and Data System category M (LR-M), CEUS LR-M category, Non-HCC malignancies
O
Proportion of CEUS LR-M in HCC and non-HCC malignancies, Frequency of individual CEUS LR-M imaging features
P
broilers
I/C
DL-methionine, L-methionine, L-methionine
O
improved average daily gain (ADG), improved feed conversion ratio (FCR)
P
hypertensive disorder, intrauterine growth restriction
I/C
l-arginine supplementation, no l-arginine supplementation
O
plasma nitric oxide concentrations, birth outcomes
P
T1DM, T2DM
I/C
insulin degludec (IDeg), insulin glargine (IGla), insulin glargine 100 U/ml (IGla100), insulin glargine 300 U/ml (IGla300)
O
glycemic variability, fasting blood glucose (FBG), standard deviation of blood glucose for 24 h, mean of 24-h blood glucose, mean amplitude of glycemic excursion, coefficient of variation for 24 h, mean of daily differences, area under the glucose curve, M-value
P
patients with hypothyroidism
I/C
L-thyroxine (L-T4) administration before breakfast, L-T4 administration at bedtime
O
hormone thyrotropin (TSH), free triiodothyronine (FT3), FT4 level
P
PD patients
I/C
Pramipexole (P) or levodopa (L) treatment, P+L combination therapy, L monotherapy
O
clinical efficacy, UPDRS scores, Hamilton depression rating scale score, adverse events
P
type 2 diabetic subjects, overweight/obese individuals
I/C
dietary anthocyanins, administration of anthocyanins, placebo
O
fasting blood sugar (FBS), 2-h postprandial glucose (2-h PPG), glycated hemoglobin (HbA1c), homeostasis model assessment of insulin resistance (HOMA-IR), resistin, plasminogen activator inhibitor-1 (PAI-1)
P
patients with liver lesions
I/C
LI-RADS algorithm, original studies reporting probability of LR-M for HCC and non-HCC malignancy on MRI
O
pooled percentages of HCC and non-HCC malignancy for LR-M, sources of heterogeneity between reported results
P
muscle-invasive bladder carcinoma
I/C
neoadjuvant PD-(L)1 inhibitors, PD-(L)1 inhibitors alone, PD-(L)1 inhibitors plus other ICI, PD-(L)1 inhibitors plus chemotherapy
O
pCR, pPR, Grade≥ 3 irAEs rate, OS, RFS